This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma.
This trial is currently open and accepting patients.
The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.
Enrollment: 288 patients (estimated)View More
Read the latest news and updates on this trial.
February 05, 2019
In patients with newly diagnosed multiple myeloma who are not eligible for stem cell transplantation, the addition of daratumumab to lenalidomide and dexamethasone significantly reduced the risk of death or disease progression by 44%, according to a late-breaking abstract presentation by Thierry Facon, MD, of the Hospital Claude Huriez in Lille, France, at the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition.
View all clinical trial locations sorted by state.